/
CVRX
$5.90+$0.03 (+0.60%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$155.5M
27M shares
52-week range
$4.37 – $11.30
22% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.44%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-22.11
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $6.3M | $6.1M | $13.0M | $22.5M | $39.3M | $51.3M | $56.7M |
| Cost of revenue | $1.7M | $1.4M | $3.6M | $5.0M | $6.3M | $8.3M | $8.3M |
| Gross profit | $4.6M | $4.6M | $9.4M | $17.5M | $33.0M | $43.0M | $48.3M |
| Gross margin | 73.1% | 76.2% | 72.1% | 77.8% | 84.1% | 83.8% | 85.3% |
| R&D | $8.7M | $6.4M | $7.5M | $10.0M | $11.6M | $11.1M | $11.1M |
| Operating income | −$10.2M | −$11.5M | −$26.0M | −$42.5M | −$43.1M | −$59.5M | −$51.3M |
| EBITDA | −$12.8M | −$11.5M | −$40.6M | −$40.7M | −$38.7M | −$54.9M | −$46.7M |
| Net income | −$14.6M | −$14.1M | −$43.1M | −$41.4M | −$41.2M | −$60.0M | −$53.3M |
| Net margin | -233.9% | -233.1% | -330.5% | -184.4% | -104.8% | -116.9% | -94.1% |
| EPS (diluted) | -0.76 | -0.73 | -2.11 | -2.02 | -1.99 | -2.65 | -2.04 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $65M | $-1.96 | $-2.11–$-1.81 | 6 |
| 2027 | $76M | $-1.89 | $-2.28–$-1.49 | 5 |
| 2028 | $96M | $-1.67 | $-2.21–$-1.05 | 4 |
| 2029 | $121M | $-1.37 | $-1.42–$-1.34 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
CVRx, Inc. Common Stock
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
www.cvrx.com- Employees
- 223
- IPO / List date
- Jun 30, 2021
- HQ
- MINNEAPOLIS, MN
Held by traders on TradeandTell
No one on the platform currently holds CVRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 19,300 | $182.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CVRX yet.
